Cambridge, UK, November 6th – CellCentric, a clinical stage biotechnology company, today announces that it will deliver an oral presentation on its groundbreaking, oral drug, inobrodib, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The presentation, set for Monday, December 9th, 2024, will be delivered by Dr. Emma Searle, Consultant Hematologist at The Christie NHS Foundation Trust.
The presentation will provide new safety and efficacy data on inobrodib, a novel p300/CBP inhibitor, currently in Phase II trials for patients with relapsed refractory multiple myeloma (RRMM). Dr. Searle will present findings on inobrodib in combination with pomalidomide and dexamethasone across several patient categories, including those refractory to, and naïve to pomalidomide, and those previously treated with an anti-BCMA or T-cell engager therapy.
Inobrodib’s novel mechanism of action distinguishes it from current therapies, providing an innovative approach for people with multiple myeloma. The initial focus is an all-oral combination, helping extend treatment options for a wider, underserved, patient population. The drug is also complementary to existing standard of care agents, and in the longer term, given its tolerability profile, holds potential in maintenance therapy.
- Novel Mechanism of Action: Inobrodib’s novel approach, through inhibiting and displacing p300 and CBP, impacts the expression of key oncogenic drivers such as MYC and IRF4.
- Safety and Efficacy Data to be Shared: Data for inobrodib + pomalidomide + dexamethasone (InoPd) in multiple myeloma patients, including those both pomalidomide-refractory and pomalidomide-naïve, as well as those that have had an anti-BCMA or T-cell engager therapy.
- New Breadth to Treating Multiple Myeloma: Inobrodib as a potential new, truly novel oral drug, expanding access to innovative therapies, particularly for patients in underserved settings.
“These findings highlight inobrodib’s promising role in reshaping multiple myeloma treatment through a novel mechanism of action and oral administration,” said Dr. Tomasz Knurowski, CMO, CellCentric. “With the potential to complement other therapies and to be used across multiple lines of treatment, inobrodib could provide a valuable new approach to meet the evolving needs of the multiple myeloma community.”
About inobrodib
Inobrodib is a novel investigational treatment for people with cancer. Delivered as an oral capsule, it is easy for patients to take. With over 400 peoples now treated, the safety profile is well characterised; it may be used by those who are unable to access or tolerate other types of treatment.
About CellCentric
CellCentric is an innovative UK-based biotechnology company with offices and operations in Cambridge, Manchester and Boston. The company was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of targeting cell fate control mechanisms. The company is now wholly focused on progressing its pioneering p300/CBP inhibitor, inobrodib, for people with cancer.
